Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 5/20 | 0.35 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.35 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.35 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL570460 | 1.00 | GRIN2D (0.35) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL5329283 | 0.74 | GRIN2D (0.37) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL5315456 | 0.73 | SLC6A12 (0.38) | — | |
| SCHEMBL24627762 | 0.72 | GRIN2D (0.36) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL29243221 | 0.71 | GRIN2D (0.39) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL31021311 | 0.71 | GRIN2D (0.39) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL22389651 | 0.69 | CYP2D6 (0.35) | — | |
| SCHEMBL2267170 | 0.69 | GRIN2D (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2267165 | 0.69 | GRIN2D (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL28773306 | 0.67 | GRIN2D (0.33) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 431 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617815-B2 | Barcoded XTEN polypeptides and compositions thereof, and methods for making and using the same | AMUNIX PHARMACEUTICALS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12589134-B2 | Compositions and methods of use of interleukin-10 in combination with immune check-point pathway inhibitors | ELI LILLY AND COMPANY (US) | 2026-03-31 | — | — | US | disclosed |
| US-20260071177-A1 | ACCELERATION OF STEM CELL DIFFERENTIATION | UNIV MINNESOTA (US) | 2026-03-12 | — | — | US | disclosed |
| US-12570981-B2 | Genetically modified mouse with conditional deletion of LRP1 in oligodendrocytes | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2026-03-10 | — | — | US | disclosed |
| US-12545739-B2 | Compositions and methods for making and using bispecific antibodies | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2026-02-10 | — | — | US | disclosed |
| US-20260021165-A1 | Extracellular Carboxylesterase 2 (CES2) for the Treatment of Metabolic Disease | UNIV LELAND STANFORD JUNIOR (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250376532-A1 | STRATEGY FOR HIGHLY SUPERIOR DR5 ACTIVATION INCLUDING IN TUMORS AND CANCERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250340624-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND REGULATING FIBRONECTIN-INTEGRIN INTERACTION AND SIGNALING | GEORGIA TECH RESEARCH CORPORATION (GE) | 2025-11-06 | — | — | US | disclosed |
| US-20250332285-A1 | ENGINEERING SUICIDE GENE APPROACHES TO IMPROVE CHEMOTHERAPEUTIC RESPONSE IN CANCER | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250332246-A1 | ENHANCED EXPRESSION VIA AUTOTRANSPORTERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-10-30 | — | — | US | disclosed |
| US-20050100963-A1 | Multimeric protein comprising endothelial growth factor (VEGF) and kinase domain region (KDR) for use in detection, prevention and treatment of cell proliferative, virral and infectious disorders | DYAX CORPORATION (US) | 2005-05-12 | — | — | US | disclosed |
| US-20050027105-A9 | Multimeric proteins for use in the treatment and detection of cell proliferative disorders | BRACCO SUISSE SA (CH) | 2005-02-03 | — | — | US | disclosed |
| EP-1482987-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2004-12-08 | — | — | EP | disclosed |
| US-20040210041-A1 | Multimeric proteins for use in the treatment and detection of cell proliferative disorders | ARBOGAST CHRISTOPHE (FR) | 2004-10-21 | — | — | US | disclosed |
| WO-2004078778-A2 | PEPTIDES THAT SPECIFICALLY BIND HGF RECEPTOR (cMet) AND USES THEREOF | DYAX CORP. (US) | 2004-09-16 | — | — | WO | disclosed |
| WO-2004065621-A1 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY | DYAX CORP. (US) | 2004-08-05 | — | — | WO | disclosed |
| WO-2004064595-A2 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL BV (NL) | 2004-08-05 | — | — | WO | disclosed |
| US-20040018974-A1 | Multivalent constructs for therapeutic and diagnostic applications | BRACCO SUISSE SA (CH) | 2004-01-29 | — | — | US | disclosed |
| WO-2003084574-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL BV (NL) | 2003-10-16 | — | — | WO | disclosed |
| WO-2003074005-A2 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY | DYAX CORP. (US) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12589134-B2 | Compositions and methods of use of interleukin-10 in combination with immune check-point pathway inhibitors | PDCD10, CD274, PDCD1LG2 | GRIN2D 4417/4885GRIN3B 4790/4885GRIN1 4260/4885 |
| US-20260021165-A1 | Extracellular Carboxylesterase 2 (CES2) for the Treatment of Metabolic Disease | CES1, CES2, CETP | GRIN2D 4302/4885GRIN3B 4835/4885GRIN1 4837/4885 |
| US-20250332285-A1 | ENGINEERING SUICIDE GENE APPROACHES TO IMPROVE CHEMOTHERAPEUTIC RESPONSE IN CANCER | ST14, MAPK14, MAP3K14 | GRIN2D 4194/4885GRIN3B 2550/4885GRIN1 3524/4885 |
| US-12570981-B2 | Genetically modified mouse with conditional deletion of LRP1 in oligodendrocytes | LDLR, MSR1, LOXL1 | GRIN2D 3208/4885GRIN3B 2972/4885GRIN1 1107/4885 |
| US-20250376532-A1 | STRATEGY FOR HIGHLY SUPERIOR DR5 ACTIVATION INCLUDING IN TUMORS AND CANCERS | TNFRSF9, TNFRSF1A, TNFSF11 | GRIN2D 3772/4885GRIN3B 673/4885GRIN1 2399/4885 |
| US-12545739-B2 | Compositions and methods for making and using bispecific antibodies | TNFRSF9, TNFRSF1A, FOLR1 | GRIN2D 1668/4885GRIN3B 931/4885GRIN1 1321/4885 |
| US-12617815-B2 | Barcoded XTEN polypeptides and compositions thereof, and methods for making and using the same | SPPL2B, PTMS, ANPEP | GRIN2D 3361/4885GRIN3B 2417/4885GRIN1 2059/4885 |
| US-20260071177-A1 | ACCELERATION OF STEM CELL DIFFERENTIATION | FGFR2, FGF2, FGF1 | GRIN2D 1572/4885GRIN3B 3550/4885GRIN1 4539/4885 |
| US-20050027105-A9 | Multimeric proteins for use in the treatment and detection of cell proliferative disorders | MKI67, TP53, VHL | GRIN2D 4678/4885GRIN3B 4637/4885GRIN1 4730/4885 |
| US-20040018974-A1 | Multivalent constructs for therapeutic and diagnostic applications | CD47, BCR, CD44 | GRIN2D 4546/4885GRIN3B 3920/4885GRIN1 4679/4885 |
| US-20250340624-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND REGULATING FIBRONECTIN-INTEGRIN INTERACTION AND SIGNALING | FN1, IGSF11, VSIG8 | GRIN2D 1896/4885GRIN3B 1950/4885GRIN1 2754/4885 |
| US-20040210041-A1 | Multimeric proteins for use in the treatment and detection of cell proliferative disorders | MKI67, TP53, VHL | GRIN2D 4678/4885GRIN3B 4637/4885GRIN1 4730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.